Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | December 16, 2025 | December 18, 2025 |
| Endo International plcENDP · Entity 124463 | Director | June 09, 2017 | June 13, 2017 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 09, 2026 | June 10, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director · Chief Executive Officer | December 07, 2025 | December 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,215 |
Reported balance
After 2025-12-16 transaction · row 1
1 source rowRow 1 · 2025-12-16 · Grant · Acquired 7,819 · Balance 46,215 F1: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date.
Endo International plc
Report date June 09, 2017 · Filed June 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,336 |
Ending reported balance
After 2017-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-06-09 · Grant · Acquired 23,934 · Balance 28,824 F1: These ordinary shares were granted to Mr. Ingram on June 9, 2017 in consideration of his services on Endo International plc's Board of Directors. Row 2 · 2017-06-09 · Tax withholding · Disposed 11,488 · Balance 17,336 F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Mr. Ingram's tax withholding obligations on shares acquired. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were granted to Mr. Ingram on June 9, 2017 in consideration of his services on Endo International plc's Board of Directors.
F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Mr. Ingram's tax withholding obligations on shares acquired.
Relay Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08 | Direct | 32,947 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Sarepta Therapeutics, Inc.
Report date December 07, 2025 · Filed December 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 929,391 |
Ending reported balance
After 2025-12-07 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2025-12-07 · Grant · Acquired 50,000 · Balance 440,307 F1: The Reporting Person was granted performance-contingent restricted stock units ("Performance-Contingent RSUs"), as described in the Company's 2018 Equity Incentive Plan. Each Performance-Contingent RSU represents the right to receive one share of common stock. The Performance-Contingent RSUs are subject to service- and performance-based vesting criteria. Row 2 · 2025-12-07 · Grant · Acquired 50,000 · Balance 490,307 F2: The Reporting Person was granted restricted shares, as described in the Company's 2018 Equity Incentive Plan. The restricted shares are subject to service- and performance-based vesting criteria. Row 3 · 2025-12-07 · Grant · Acquired 73,001 · Balance 563,308 F3: The Reporting Person was granted Performance Units, as described in the Company's 2018 Equity Incentive Plan. The Performance Units are subject to service- and performance-based vesting criteria. Row 4 · 2025-12-07 · Grant · Acquired 96,541 · Balance 659,849 F4: The Reporting Person was granted Performance Shares, as described in the Company's 2018 Equity Incentive Plan. The Performance Shares are subject to service- and performance-based vesting criteria. Row 5 · 2025-12-07 · Grant · Acquired 269,542 · Balance 929,391 F5: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs are subject to service- and performance-based vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted performance-contingent restricted stock units ("Performance-Contingent RSUs"), as described in the Company's 2018 Equity Incentive Plan. Each Performance-Contingent RSU represents the right to receive one share of common stock. The Performance-Contingent RSUs are subject to service- and performance-based vesting criteria.
F2: The Reporting Person was granted restricted shares, as described in the Company's 2018 Equity Incentive Plan. The restricted shares are subject to service- and performance-based vesting criteria.
F3: The Reporting Person was granted Performance Units, as described in the Company's 2018 Equity Incentive Plan. The Performance Units are subject to service- and performance-based vesting criteria.
F4: The Reporting Person was granted Performance Shares, as described in the Company's 2018 Equity Incentive Plan. The Performance Shares are subject to service- and performance-based vesting criteria.
F5: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs are subject to service- and performance-based vesting criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 32,947 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-265905 · ownership.xml · derivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,947 Underlying: Common Stock · 32,947 shares Expires 2036-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:39 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001190644-25-000004 · wk-form4_1766101193.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,215 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| December 07, 2025 Filed Dec 10, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 269,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-313184 · ownership.xml · nonDerivative · entry 5 INGRAM DOUGLAS S · CIK 0001190644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,391 F5 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs are subject to service- and performance-based vesting criteria. Read SEC document |
| December 07, 2025 Filed Dec 10, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 96,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-313184 · ownership.xml · nonDerivative · entry 4 INGRAM DOUGLAS S · CIK 0001190644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,849 F4 · shares: The Reporting Person was granted Performance Shares, as described in the Company's 2018 Equity Incentive Plan. The Performance Shares are subject to service- and performance-based vesting criteria. Read SEC document |
| December 07, 2025 Filed Dec 10, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 73,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-313184 · ownership.xml · nonDerivative · entry 3 INGRAM DOUGLAS S · CIK 0001190644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,308 F3 · shares: The Reporting Person was granted Performance Units, as described in the Company's 2018 Equity Incentive Plan. The Performance Units are subject to service- and performance-based vesting criteria. Read SEC document |
| December 07, 2025 Filed Dec 10, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-313184 · ownership.xml · nonDerivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,307 F2 · shares: The Reporting Person was granted restricted shares, as described in the Company's 2018 Equity Incentive Plan. The restricted shares are subject to service- and performance-based vesting criteria. Read SEC document |
| December 07, 2025 Filed Dec 10, 2025 01:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-313184 · ownership.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,307 F1 · shares: The Reporting Person was granted performance-contingent restricted stock units ("Performance-Contingent RSUs"), as described in the Company's 2018 Equity Incentive Plan. Each Performance-Contingent RSU represents the right to receive one share of common stock. The Performance-Contingent RSUs are subject to service- and performance-based vesting criteria. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 21:51 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 136,681 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000950170-25-083311 · ownership.xml · derivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,681 Underlying: Common Stock · 136,681 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 38,396 | $20.09 | $771,375.64 |
DisclosureSEC source: 0001628280-25-004478 · wk-form4_1738969065.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,396 F1 · shares: Represents shares underlying restricted stock units with a grant date 02/06/2025, which will vest in three years. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:03 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 102,225 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000950170-24-069556 · ownership.xml · derivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,225 Underlying: Common Stock · 102,225 shares Expires 2034-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 200 | $81.26 | $16,252.00 |
DisclosureSEC source: 0001209191-23-054441 · doc4.xml · nonDerivative · entry 4 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,307 Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 3,884 | $80.33 | $312,001.72 |
DisclosureSEC source: 0001209191-23-054441 · doc4.xml · nonDerivative · entry 3 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,107 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 11,060 | $79.70 | $881,482.00 |
DisclosureSEC source: 0001209191-23-054441 · doc4.xml · nonDerivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,223 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 10,081 | $78.57 | $792,064.17 |
DisclosureSEC source: 0001209191-23-054441 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,163 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 22:42 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 66,055 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001209191-23-033442 · doc4.xml · derivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,055 Underlying: Common Stock · 66,055 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| May 27, 2022 Filed May 27, 2022 21:39 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 41,597 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001209191-22-032682 · doc4.xml · derivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Common Stock · 41,597 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 23:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 25,026 | $79.94 | $2,000,578.44 |
DisclosureSEC source: 0001209191-21-065246 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,082 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.62 to $80.06, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| June 26, 2021 Filed Jun 29, 2021 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 17,812 | $80.40 | $1,432,084.80 |
DisclosureSEC source: 0001209191-21-043582 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,056 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · acquired: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. Read SEC document |
| May 19, 2021 Filed May 21, 2021 23:42 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001209191-21-035112 · doc4.xml · derivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 37,144 | $170.49 | $6,332,680.56 |
DisclosureSEC source: 0001209191-21-000556 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,868 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · acquired: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0000899243-20-019841 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: On July 20, 2020, the reporting person purchased 25,000 shares of common stock, par value $0.001 per share, of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering. Read SEC document |
| December 31, 2019 Filed Jan 4, 2020 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 37,185 | $129.04 | $4,798,352.40 |
DisclosureSEC source: 0001209191-20-001424 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,012 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. F1 · acquired: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 21:48 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 7,792 | $123.41 | $961,610.72 |
DisclosureSEC source: 0001209191-19-045578 · doc4.xml · nonDerivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,197 F2 · price: The shares were purchased in multiple transactions at prices ranging from $123.22 to $123.79, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 21:48 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 8,460 | $122.76 | $1,038,549.60 |
DisclosureSEC source: 0001209191-19-045578 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,405 F1 · price: The shares were purchased in multiple transactions at prices ranging from $122.16 to $123.00, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2018 Filed Oct 30, 2018 23:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 3,134 | $120.94 | $379,025.96 |
DisclosureSEC source: 0001209191-18-056571 · doc4.xml · nonDerivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,945 F2 · price: The shares were purchased in multiple transactions at prices ranging from $120.81 to $121.00, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2018 Filed Oct 30, 2018 23:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 13,561 | $120.26 | $1,630,845.86 |
DisclosureSEC source: 0001209191-18-056571 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,811 F1 · price: The shares were purchased in multiple transactions at prices ranging from $119.78 to $120.78, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 11:30 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 16,000 | $125.26 | $2,004,211.20 |
DisclosureSEC source: 0001209191-18-046916 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,250 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.97 to $126.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 21:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 36,946 | $135.53 | $5,007,291.38 |
DisclosureSEC source: 0001209191-18-039689 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,250 F1 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of a restricted stock award granted on June 26, 2017. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 22:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 38,138 | $52.44 | $1,999,956.72 |
DisclosureSEC source: 0000899243-17-026060 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,196 Read SEC document |
| July 27, 2017 Filed Jul 28, 2017 12:51 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | PurchaseCommon Stock | 47,058 | $42.50 | $1,999,965.00 |
DisclosureSEC source: 0001209191-17-046510 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,058 Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:50 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,300,000 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001209191-17-042164 · doc4.xml · derivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300,000 Underlying: Common Stock · 3,300,000 shares Expires 2027-06-26 F2 · derivative.exercise_date: On June 26, 2022, subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through such date, a percentage of the stock options will vest based on the extent to which the compounded annual growth rate ("CAGR") of the Issuer's stock price from June 26, 2017 (based on the closing price on such date) through June 26, 2022 (based on the average of the closing price of the Issuer's common stock on the 20 days immediately preceding such date) exceeds the CAGR of the NASDAQ Biotech Index (or any successor index) during the same period. F3 · derivative.expiration_date: In certain situations, the stock options will expire within twelve months of such situation, but in no event will the stock options be exercisable after June 26, 2027. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:50 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 335,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042164 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 F1 · shares: Represents shares of restricted stock. Twenty-five percent of the shares will vest on June 26, 2018 and one thirty-sixth of the remaining unvested shares will vest on each monthly anniversary of June 26 thereafter, ending on June 26, 2021, in each case subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through each applicable vesting date. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 01:40 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 11,488 | $11.49 | $131,997.12 |
DisclosureSEC source: 0001209191-17-039330 · doc4.xml · nonDerivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,336 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Mr. Ingram's tax withholding obligations on shares acquired. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 01:40 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 23,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039330 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,824 F1 · kind: These ordinary shares were granted to Mr. Ingram on June 9, 2017 in consideration of his services on Endo International plc's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.